Home About
Back to Search

Veklury

REMDESIVIR

Manufacturer: Gilead Sciences, Inc.

Score: 141.0

Quick Summary

Veklury (remdesivir) is an antiviral medication used for the treatment of COVID-19 in adults and pediatric patients. It has shown efficacy in reducing the risk of hospitalization and improving clinical outcomes. However, it is not recommended for use in patients with a history of clinically significant hypersensitivity reactions to Veklury or its components. The medication should be administered via intravenous infusion, and the recommended dosage varies based on patient population and renal function.

Key Clinical Findings and Indications

  • Treatment of COVID-19 in adults and pediatric patients
  • Reduces risk of hospitalization and improves clinical outcomes
  • Effective against various SARS-CoV-2 variants

Important Safety Information

Warning

Contraindicated in patients with a history of clinically significant hypersensitivity reactions to Veklury or its components

Contraindications

  • History of clinically significant hypersensitivity reactions to Veklury or its components

Adverse Reactions

  • Nausea
  • ALT increased
  • AST increased
  • Hypersensitivity reactions
  • Anaphylaxis

Dosing Recommendations

General Guidance

No dosage adjustment is recommended in patients with any degree of renal impairment, including those on dialysis

COVID-19

Adult Dose

200 mg on Day 1, followed by 100 mg once daily

Pediatric Dose

Weight-based dosing, 5 mg/kg on Day 1, followed by 2.5 mg/kg once daily

Special Population Considerations

Pregnancy

  • No clinically relevant differences in pharmacokinetics between pregnant and non-pregnant individuals
  • Use during pregnancy should be based on clinical judgment

Nursing Mothers

  • No data available on the presence of remdesivir in human milk
  • Caution should be exercised when administering Veklury to nursing mothers

Pediatric Use

  • Safety and effectiveness established in pediatric patients from birth to less than 18 years of age and weighing at least 1.5 kg
  • Use in pediatric patients weighing less than 1.5 kg has not been established

Geriatric Use

  • No differences in responses between elderly and younger patients
  • Appropriate caution should be exercised in the administration of Veklury and monitoring of elderly patients

Similar Drugs

INFLIXIMAB

INFLIXIMAB

Janssen Biotech, Inc.

Similarity: 60.5%

REMICADE

INFLIXIMAB

Janssen Biotech, Inc.

Similarity: 60.5%

Renflexis

INFLIXIMAB

Merck Sharp & Dohme LLC

Similarity: 60.5%
Back to Search